+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Epilepsy Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • ID: 4896051
  • Report
  • June 2022
  • Region: Global
  • 114 Pages
  • Mordor Intelligence


  • Abbott Laboratories
  • Alkem Labs.
  • Eisai Co., Ltd.
  • GlaxoSmithKline PLC
  • GW Pharmaceuticals plc
  • H. Lundbeck A/S
The epilepsy drugs market is projected to register a CAGR of 3.5% during the forecast period (2022-2027).

Neurology activities, such as medical training and research, were disrupted as a result of the pandemic. COVID-19 has a social impact not only on epilepsy patients but also on epilepsy treatment centers. Patients' access to healthcare facilities has been severely limited due to the risk of SARS-CoV-2 transmission from patient to patient or from healthcare provider to patient. Furthermore, due to concerns about patient-to-patient transmission, standby admissions in hospitals with COVID-19 inpatients or in areas with widespread COVID-19 infection have been severely limited. According to an article published in March 2020 titled "Epilepsy and COVID-19: Updated Evidence and Narrative Review," a survey of 212 pediatric neurologists from 49 countries found that in-person outpatient visits have decreased and telemedicine use has increased during the pandemic.

Epilepsy is a central nervous system (CNS) disorder in which brain activity becomes abnormal, resulting in seizures or periods of unusual behavior, and sensations. It can occur due to a genetic disorder or an acquired brain injury. The major factors for the growth of the epilepsy drugs market include the rise in the new drug approvals over the past few years and increasing cases of epilepsy across the globe. As per the World Health Organization facts of 2022, around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. In high-income countries, there are estimated to be 49 per 100 000 people diagnosed with epilepsy each year. In low- and middle-income countries, this figure can be as high as 139 per 100 000. There is also rising awareness levels about epilepsy coupled with strategic alliances that are anticipated to stimulate the market growth. One of the organization Epilepsy Foundation is promoting public awareness and education by undertaking research and delivering specialist medical care and support services to the people affected by epilepsy.

Key Market Trends

Second Generation Anti-epileptics is the Segment by Drugs Expected to Hold a Large Market Share Over the Forecast Period

The second-generation anti-epileptics drugs are expected to hold the largest market share owing to the several significant advantages such as reduced drug-drug interactions, less life-threatening adverse events and less negative impact on cognitive functions.

Furthermore, the rising cases of epilepsy will boost the demand for drugs in the market. Also, recently in February 2021, Dr Reddy’s Laboratories launched Vigabatrin tablets, an antiepileptic drug in the United States market after receiving approval from the United States Food and Drug Administration (US FDA). Besides, the market players are also acquiring other firms to expand their product portfolio. For instance, in January 2022, UCB announced that it has acquired Zogenix for USD 1.9 billion in a bid to bolster its epilepsy portfolio by adding Fintepla (fenfluramine), a marketed drug for the treatment of seizures associated with Dravet syndrome, a rare form of childhood epilepsy. Having gained a newly marketed product for patients with rare and difficult-to-treat pediatric orphan epilepsy syndromes, this deal continues to expand UCB’s extensive therapeutic offering in the epilepsy market. Hence, owing to the new product launch and acceptance of second-generation epilepsy drugs the market is expected to witness high growth over the forecast period.

North America is Expected to Hold Largest Market Share over the Forecast Period

The COVID-19 pandemic has impacted the delivery of care to people with epilepsy (PWE) in many ways including limitations on in-person contact and restrictions on neurophysiological procedures. According to a study titled "The Impact of COVID-19 on Epilepsy Care: A Survey of the American Epilepsy Society Membership" published in September 2020, 10% of respondents reported a worsening in seizure frequency, while 5% reported an improvement. Increased stress, sleep deprivation, and limited access to pharmacies and medications have all been linked to an increase in seizure frequency.

Also, according to the resaerch article published in 2020 titled "The Impact of COVID-19 on Epilepsy Care: A Survey of the American Epilepsy Society Membership", during the pandemic, epilepsy patients faced a number of barriers to receiving appropriate clinical care, including loss of employment and financial stress, lack of access to health care due to closure, transportation issues, lack of access to technology for telehealth, and a fear of a viral outbreak. During this time, however, nearly 90% of respondents indicated a willingness to use telehealth.

The United States is expected to be the largest epilepsy drug market owing to the presence of better healthcare infrastructure and rising cases of epilepsy. As per the Centre for Disease Control and Prevention 2020, about 470,000 children and around 3 million adults have active epilepsy in the United States.The number of Americans who have epilepsy is greater than the number who have multiple sclerosis, Parkinson’s disease, and cerebral palsy combined. Thus, there is a rising demand for effective treatment in the region which is expected to boost the growth of the epilepsy drug market.

Furthermore, there are various organizations making awareness about epilepsy in the United States. For instance, Epilepsy Awareness Day, or Purple Day, is celebrated annually on 26th March to increase the public’s understanding of this brain disorder and to eliminate the fear and stigma surrounding it. Thus, owing to the all above-mentioned factors the market is expected to witness high growth.

Competitive Landscape

The market studied is a consolidated market owing to the presence of a few major market players. Therefore most of the key players are found focusing on the expansion of their businesses to increase their market share. Also, they are adopting certain strategies, such as new product development, mergers, and acquisitions. Some of the players operating in the market are Abbott Laboratories, GlaxoSmithKline PLC, Johnson & Johnson, Novartis AG, Pfizer, Inc., Sanofi SA, Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, and UCB S.A.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • Abbott Laboratories
  • Alkem Labs.
  • Eisai Co., Ltd.
  • GlaxoSmithKline PLC
  • GW Pharmaceuticals plc
  • H. Lundbeck A/S

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in the New Drug Approvals over the Past Few Years
4.2.2 Increase in the Cases of Epilepsy
4.3 Market Restraints
4.3.1 Side Effects Associated With the Drugs
4.3.2 Recent Patent Expiration of Major Brands
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Drugs
5.1.1 First Generation Anti-epileptics
5.1.2 Second Generation Anti-epileptics
5.1.3 Third Generation Anti-epileptics
5.2 By Distribution Channel
5.2.1 Hospital Pharmacy
5.2.2 Pharmacy Stores
5.2.3 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 GlaxoSmithKline PLC
6.1.3 Johnson & Johnson
6.1.4 Novartis AG
6.1.5 Pfizer, Inc.
6.1.6 Sanofi SA
6.1.7 Sunovion Pharmaceuticals Inc.
6.1.8 Takeda Pharmaceutical Company Limited
6.1.9 UCB S.A.,
6.1.10 Sun Pharmaceutical Industries Limited
6.1.11 GW Pharmaceuticals plc
6.1.12 H. Lundbeck A/S
6.1.13 Alkem Labs.
6.1.14 Eisai Co., Ltd.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • UCB S.A.,
  • Sun Pharmaceutical Industries Limited
  • GW Pharmaceuticals plc
  • H. Lundbeck A/S
  • Alkem Labs.
  • Eisai Co., Ltd.
Note: Product cover images may vary from those shown